Sorry, you need to enable JavaScript to visit this website.

Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Pregnant Women and their Infants

Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Pregnant Women and their Infants. Final Report: A Phase 2b, Randomized, Placebo-Controlled, Observer-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine in Pregnant Women 18 Through 49 Years of Age and Their Infants.

Category & Conditions: Vaccine-related Conditions
Medicine: PF-06928316
ClinicalTrials.gov Identifier (NCT): NCT04032093
Protocol ID: C3671003
    Share
PrintDownload
Open Plain Language Summary Result: Click here